Wegovy® vs Foundayo®
Both FDA-approved for weight loss — but one is a weekly injection and the other is a daily pill you can take any time, anywhere.
BestGLP1 is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S, Eli Lilly and Company, or any other manufacturer named on this page. All trademarks are the property of their respective owners.
14.9%
Avg weight loss Wegovy*
From
$199/mo
Wegovy
June 2026
12.4%
Avg weight loss Foundayo*
From
$149/mo
Foundayo
June 2026
What are they?
Wegovy is the leading injectable semaglutide for obesity. Foundayo is the first oral GLP-1 weight-loss pill with no food or water restrictions.
Wegovy
Weight ManagementFDA-approved specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition.
Maker
Novo Nordisk
Approved
2021
Format
Weekly injection or daily pill
Max dose
2.4 mg
Foundayo
Weight ManagementFDA-approved oral GLP-1 receptor agonist for chronic weight management — the first weight-loss pill that can be taken at any time of day with no food or water restrictions. Made by Eli Lilly, approved April 2026.
Maker
Eli Lilly
Approved
2026
Format
Daily oral pill
Max dose
17.2 mg
Quick comparison
How they stack up on the metrics that matter most.
| Feature | Wegovy | Foundayo |
|---|---|---|
| Active ingredient | Semaglutide | Orforglipron |
| FDA approved for | Weight loss | Weight Management |
| Avg weight loss | 14.9%† | 12.4%† |
| Administration | Weekly injection or daily pill | Daily oral pill |
| Insurance | Limited | Limited |
| Monthly Price | From $199/mo | From $149/mo |
Wegovy
Semaglutide
Foundayo
Orforglipron
Wegovy
Weight loss
Foundayo
Weight Management
Wegovy
14.9%†
Foundayo
12.4%†
Wegovy
Weekly injection or daily pill
Foundayo
Daily oral pill
Wegovy
Limited
Foundayo
Limited
Wegovy
From $199/mo
Foundayo
From $149/mo
† Average weight loss data: Wegovy — STEP-1 (semaglutide 2.4 mg, 68 weeks); Foundayo — ATTAIN-1 (oral orforglipron 36 mg, 72 weeks).
More energy,
less weight
How you ramp up
Both medications use a gradual dose escalation to minimize side effects.
Wegovy
- 1
0.25 mg
Weeks 1–4
- 2
0.5 mg
Weeks 5–8
- 3
1.0 mg
Weeks 9–12
- 4
1.7 mg
Weeks 13–16
- 5
2.4 mg
Weeks 17+
(Maintenance)
- 6
7.2 mg
Weeks 21+
(After 4+ wks at 2.4 mg)
Foundayo
- 1
0.8 mg
Month 1
(Daily)
- 2
2.5 mg
Month 2
(Daily)
- 3
5.5 mg
Month 3
(Daily)
- 4
9 mg
Month 4
(Daily)
- 5
14.5 mg
Month 5
(Daily)
- 6
17.2 mg
Month 6+
(Maintenance)
Start your weight‑loss
journey today
Weight loss compared
Clinical trial data showing average body weight reduction over 68 weeks.
Wegovy (2.4 mg)
Foundayo (17.2 mg)
† Average weight loss data: Wegovy — STEP-1 (semaglutide 2.4 mg, 68 weeks); Foundayo — ATTAIN-1 (oral orforglipron 36 mg, 72 weeks).
What to expect
How they stack up on the metrics that matter most.
| Side Effect | Wegovy (2.4 mg) | Foundayo (36 mg) |
|---|---|---|
| Nausea | 44% | ~33.7% |
| Diarrhea | 30% | ~23.1% |
| Vomiting | 24% | ~24.0% |
| Constipation | 24% | ~25.4% |
| Headache | 14% | ~9% |
| Fatigue | 11% | ~9% |
Wegovy (2.4 mg)
44%
Foundayo (36 mg)
~33.7%
Wegovy (2.4 mg)
30%
Foundayo (36 mg)
~23.1%
Wegovy (2.4 mg)
24%
Foundayo (36 mg)
~24.0%
Wegovy (2.4 mg)
24%
Foundayo (36 mg)
~25.4%
Wegovy (2.4 mg)
14%
Foundayo (36 mg)
~9%
Wegovy (2.4 mg)
11%
Foundayo (36 mg)
~9%
Side effects may be more noticeable during dose escalation, but individual experiences vary and some risks can be serious. GLP-1 medications are not appropriate for everyone. Review important warnings, contraindications, and the FDA label or Medication Guide with a licensed healthcare provider before starting or switching treatment.
The bottom line
Branded GLP-1 medications can offer effective weight loss, requiring individualized risk-benefit clinical evaluation.
Two different GLP-1 options
- Wegovy delivers substantial weight loss, weekly convenience, appetite control, and cardiovascular risk reduction backed by robust obesity-focused clinical trial evidence and safety data.
- Foundayo is an oral GLP-1 medication FDA-approved for chronic weight management in eligible adults. It is taken once daily and may be suitable for patients who prefer an oral option to injectables.
Providers may pay BestGLP1 a referral fee. We disclose this for FTC compliance; rankings remain editorial.
What you
need to know
On average, no — trial data shows Wegovy at ~15% body-weight reduction vs ~11.1% for Foundayo. That said, Foundayo is meaningfully more convenient (oral, no food/water timing), so the right choice depends on whether absolute results or fit-into-life convenience matters more to you.
Yes — switching from Wegovy to Foundayo is straightforward with provider guidance. They’ll typically restart you at the lowest Foundayo dose and titrate up over several months to manage tolerability, then monitor results to confirm the new medication is working as expected.
Coverage is still expanding for Foundayo, since it was approved in April 2026. Some plans cover it under their weight-management benefit; many don’t yet. Check your formulary, and consider telehealth pricing (from $149/month) if your plan doesn’t cover it.
Foundayo is an oral pill (no injections), can be taken at any time of day without food or water restrictions, and has a lower retail price than Wegovy. Patients who dislike needles or struggle to keep weekly injection schedules often find it dramatically easier to stay on long term.
Yes. Both Wegovy and Foundayo require a prescription from a licensed healthcare provider. A consultation is required to assess whether treatment is appropriate for you.
- Wegovy (semaglutide 2.4 mg). Trial: STEP 1 (1,961 participants, 68 weeks, adults with obesity/overweight without Type 2 Diabetes). Average weight loss: −14.9% vs −2.4% placebo. Wilding et al., NEJM 2021.
- Foundayo (orforglipron, 36 mg capsule / 17.2 mg tablet equivalent). Trial: ATTAIN-1 (3,127 participants, 72 weeks, adults with obesity or overweight without diabetes). Average weight loss: ~12.4% vs 0.9% placebo.
BestGLP1 publishes these guides for informational and comparison purposes only. The information on this site is not medical advice, diagnosis, or treatment, and is not a substitute for guidance from a licensed healthcare professional. GLP-1 medications must be prescribed and monitored by a qualified provider; consult your provider to determine whether treatment is appropriate for your individual circumstances. Prices, side-effect rates, and clinical figures shown here are general references drawn from manufacturer labelling and published trials, and may not reflect your specific situation.
Find the right
GLP-1 for you
Compare side by side. No signup required.
What's your
target weight?
Let's find your perfect program
Providers may pay BestGLP1 a referral fee. We disclose this for FTC compliance; rankings remain editorial.